On October 22, Samsung Biologics announced it signed a long term partnership with Roche Group of Switzerland to produce biopharmaceuticals.
Through the partnership, Samsung will produce Roche’s biopharmaceuticals from two biotech plants in Songdo’s Incheon Free Economic Zone. The second production facility is currently under construction. The details on the production items and contract terms have not yet been disclosed.
David Lapre, Head of Global Pharma Technical Operations at Roche, said, “Samsung has outstanding production capabilities, and based on this belief, the partnership was signed.” He added, “Through this partnership, I look forward to the demands for Roche’s revolutionary pharmaceuticals being met.”
Samsung Biologics CEO Kim Tae-han said, “Samsung will be providing the world’s best production services, strictly following the global quality standards for biopharmaceuticals,” and emphasized, “This partnership with the world’s best biopharmaceutical company is a crucial milestone supporting Samsung’s medium and long-term strategy to become a global leader in the biopharmaceutical production industry.”